Press Releases BioPorto A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-06-10 am EDT			5-day change	1st Jan Change
1.63 ^DKK	-1.57%		-3.89%	-22.01%

May. 30	BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024	CI
May. 30	BioPorto A/S Appoints Niels Høy Nielsen as Chief Financial Officer, Effective August 1, 2024	CI

BioPorto A/S Appoints Chief Financial Officer	May. 30	GL
First Quarter 2024: Strong growth in US sales of The NGAL Test	May. 08	GL
Resolutions of Annual Geneal Meeting	Apr. 30	GL
Grant of warrants	Apr. 23	GL
BioPorto A/S Appoints Chief Legal Officer	Apr. 10	GL
New Board Candidate for the upcoming Annual Geneal Meeting	Apr. 05	GL
Notice convening the Annual General Meeting in BioPorto A/S	Apr. 04	GL
Correction: BioPorto Announces Annual Results for 2023	Apr. 04	GL
BioPorto Announces Annual Results for 2023	Apr. 04	AQ
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer	Apr. 02	GL
BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026	Feb. 22	GL
Roche Diagnostics and BioPorto expand collaboration	Feb. 20	GL
BioPorto implements changes to the Executive Management.	Jan. 09	GL
Managers’ transactions	Dec. 09	AQ
Managers’ transactions	Dec. 09	GL
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years	Dec. 07	GL
Resignation of Director	Dec. 04	GL
BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023	Nov. 01	GL
BioPorto provides interim Q3 results and revised 2023 Financial Guidance.	23-10-31	GL
BioPorto provides interim Q3 results and revised 2023 Financial Guidance.	23-10-31	AQ

No results for this search